Europe Neoantigen Summit 2022


Maik Pruess

Maik Pruess, PhD
Senior Field Application Scientist
Personalis, Inc.

April 27, 2022 | 10:10 AM GMT

Don’t miss what’s (ImmunoID) NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics, and Immunogenomics Profiling 

  • Accurate assessment of mutational landscape and putative neoantigens from the analytically-validated exome and transcriptome ImmunoID NeXT platform
  • Improved neoantigen presentation and binding predictions through a machine learning algorithm, SHERPA, built upon high quality immunopeptidomics training data from mono-allelic, and multi-allelic samples
  • Comprehensive immunogenomics profiling from a single sample to guide neoantigen-based therapies today and enable future biomarker discovery

Connect with us at Europe Neoantigen Summit 2022